EpiPen maker boosts discount programs but holds price steady, despite outrage

Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has climbed more than 500% over the last decade.

But the drugmaker didn't budge on its price, which has drawn ire both in Congress and from...